AVEO: Longer PFS And Remarkable Safety Profile Will Differentiate Our Kidney Cancer Drug

In an exclusive video interview with PropThink.com, Michael Bailey, Chief Commercial Officer of AVEO Pharmaceuticals (NASDAQ:AVEO), explains the benefits of AVEO’s Phase III drug candidate Tivozanib in renal cell carcinoma, citing lower toxicity than existing drugs and extended progression-free survival (PFS). Bailey also discusses the company’s current partnerships with Astellas Pharma (OTC:ALPMY) and Biogen Idec (NASDAQ:BIIB) in developing two of their three pipeline compounds and talks about AVEO’s filing expectations for Q3 2012 and strategy entering the next year of commercialization.